Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02536170 · ClinicalTrials.gov registry record · Phase 2
Arginine Therapy for Sickle Cell Disease Pain
A Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 108
- Enrollment target
- 3
- Study locations
NCT02536170: Completed Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode, sponsored by Emory University.
NCT02536170 is a Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode that has completed, run by Emory University. The registered enrollment target is 108 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (63% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02536170, a Phase 2 study of Sickle Cell Disease and Vaso-occlusive Pain Episode, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 108 participants
- Enrollment target
- 3
- Study locations
Study Summary
The aim of this study is to determine whether giving extra arginine, a simple amino acid, to patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful events (VOE) will decrease pain scores, decrease the need for pain medications or decrease length of hospital stay or emergency department visit. Funding Source - FDA OOPD.
Primary Outcome
The total amount of parenteral opioids used by participants measured in mg/kg of IV morphine equivalents. The total is calculated after study drug delivery for participants in the emergency department (ED) and during hospital stay.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG L-arginine
- DRUG L-arginine Loading Dose
Study Locations (3)
Georgia
- Children's Healthcare of Atlanta at Hugh Spalding - Atlanta
- Children's Healthcare of Atlanta at Egleston - Atlanta
- Children's Healthcare of Atlanta at Scottish Rite - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 108 participants |
| Start Date | 2016-02 |
| Est. Completion | 2021-02-21 |
| Phase | Phase 2 |
What the finished NCT02536170 record still lists
NCT02536170 is an interventional study that assigns participants to a tested intervention. The registered 108 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Sickle Cell Disease appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT02536170 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT02536170 about?
NCT02536170 is a clinical study titled "Arginine Therapy for Sickle Cell Disease Pain". The aim of this study is to determine whether giving extra arginine, a simple amino acid, to patients with sickle cell disease seeking treatment for a pain crisis (vaso-occlusive painful events (VOE) will decrease pain scores, decrease the need for pain medications or decrease length of hospital sta...
What is the current status of trial NCT02536170?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 108 participants. The study started on 2016-02. Estimated completion is 2021-02-21.
What conditions does trial NCT02536170 study?
This clinical trial studies the following conditions: Sickle Cell Disease, Vaso-occlusive Pain Episode.
What interventions are being tested in trial NCT02536170?
The interventions under investigation include: Placebo (OTHER), L-arginine (DRUG), L-arginine Loading Dose (DRUG).
Who is sponsoring clinical trial NCT02536170?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02536170 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02536170's enrollment target sits among peer trials
108 58th of 213 higher than 156 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02703207 · 108 participants · NA
Neurocognitive and Health Impact of Sleep Apnea in Elderly Veterans With Comorbid COPD
- NCT02744677 · 108 participants · NA
COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction
- NCT02781883 · 108 participants · Phase 2
Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML
- NCT03848663 · 108 participants · NA
Visual Remapping to Aid Reading With Field Loss
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia